Corporate Actions › Sub-category

M&A / Stake Purchase / Joint Venture

1 article

Strides Pharma Q2 FY26 Consolidated Revenue Rises 17% YoY

Strides Pharma reported unaudited consolidated financial results for Q2 and H1 FY26, showing revenue growth of 17% YoY to ₹14,297 million in Q2. The Board approved results including a net profit of ₹1